Biogen Cash Flow Statement
BIIB / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
$2.2B
FY2025
Free Cash Flow
$2.1B
FY2025
Capital Expenditures
$154M
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Biogen generated $2.2B in operating cash flow and $2.1B in free cash flow in FY2025. Free cash flow margin was 20.7% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $1.3B | $1.6B | $1.2B | $3.0B | $1.6B | $4.0B | $5.9B | $4.4B | $2.5B | $3.7B | $3.5B | $2.9B | $1.9B | $1.4B | $1.2B |
| Depreciation & Amortization | $779.9M | $673.2M | $494.8M | $518.4M | $487.7M | $457.2M | $464.7M | $650.5M | $1.1B | $682.7M | $600.4M | $688.1M | $531.7M | $365.6M | $358.9M |
| Operating Cash Flow | $2.2B | $2.9B | $1.5B | $1.4B | $3.6B | $4.2B | $7.1B | $6.2B | $4.6B | $4.6B | $3.9B | $2.9B | $2.3B | $1.9B | $1.7B |
| Capital Expenditures | $153.8M | $153.7M | $277.0M | $240.3M | $258.1M | $424.8M | $514.5M | $770.6M | $867.4M | $616.1M | $643.0M | $287.8M | $246.3M | $254.5M | $208.0M |
| Free Cash Flow | $2.1B | $2.7B | $1.3B | $1.1B | $3.4B | $3.8B | $6.6B | $5.4B | $3.7B | $4.0B | $3.3B | $2.7B | $2.1B | $1.6B | $1.5B |
| Share Buybacks | - | $0 | $0 | $750.0M | $1.8B | $6.7B | $5.9B | $4.4B | $1.4B | $1.0B | $5.0B | $886.8M | $400.3M | $984.7M | $498.0M |
| FCF Margin | 20.7% | 28.1% | 12.9% | 11.3% | 30.8% | 28.3% | 45.6% | 40.3% | 30.0% | 34.7% | 30.4% | 27.4% | 30.3% | 29.5% | 30.1% |